


## Supplemental Material


**Table S1** Name, type, dilution, and source of primary antibodies<sup>1</sup>

Antibody	Isotype	Dilution	Source
Primary Antibody			
TLR4	Rabbit	1:1000	ABclonal (Wuhan, China)
MyD88	Rabbit	1:1000	ABclonal (Wuhan, China)
TRAF6	Rabbit	1:1000	ABclonal (Wuhan, China)
NF- $\kappa$ B	Rabbit	1:1000	ABclonal (Wuhan, China)
p53	Rabbit	1:1000	ABclonal (Wuhan, China)
BCL2	Rabbit	1:1000	ABclonal (Wuhan, China)
$\beta$ -actin	Rabbit	1:10000	ABclonal (Wuhan, China)
Secondary Antibody			
HRP labelled Antibody	Goat anti rabbit	1:10000	ABclonal (Wuhan, China)

<sup>1</sup>TLR4, toll like receptor 4; MyD88, myeloid differentiation factor 88; TRAF6, TNF- $\alpha$  receptor-associated factor 6; NF- $\kappa$ B, nuclear transcription factor kappaB; p53, tumor protein p53; BCL2, B-cell lymphoma 2.



**Figure S1** Schematic of the experimental procedure of the animal trial



**Figure S2** Validation of the specificity of antibodies against and the correct bands of TRL4, MyD88, TRAF6, NF- $\kappa$ B, p53, and BCL2. Western blot gel bands of TRL4 (A), MyD88 (B), TRAF6 (C), NF- $\kappa$ B (D) and p53 (E) were verified with piglet liver samples, and BCL2 (F) was verified with piglet spleen samples.